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Abstract
Background: Prognosis among patients with differentiated thyroid cancer is widely
variable. Better understanding of biologic subtypes is necessary to stratify patients
and improve outcomes.
Methods: In patients diagnosed with classic histology papillary thyroid cancer
treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical
tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by
immunohistochemistry for RET, phospho‐MEK, MAPK(dpERK), PPARγ, and
phospho‐AKT(pAKT). Stained slides were scored independently and blindly by two
investigators and compared to tumor and patient characteristics and outcomes.
Results: A total of 231 patients had archived formalin‐fixed, paraffin‐embedded
tumor tissue available and were included on the TMA. Mean age at diagnosis was
44 years (range 6‐82 years); proportion of patients with female sex was (72%); 2015
American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens,
and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ
(27%), and pAKT (39%). Positive RET staining was associated with a lower risk of
recurrence (HR = 0.46, 95% CI 0.22‐0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with
RET‐negative and either MAPK(dpERK)‐positive or pAKT‐positive tumors were
identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5‐11.7). This profile
remained associated with recurrence in a multivariable model including ATA risk
stratification (HR = 2.8, 95% CI 1.3‐6.0).
Conclusion: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk
categories alone.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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IN TRO D U C T ION

Thyroid cancer represents the most common endocrine malignancy, accounting for an estimated 53 990 new diagnoses in the United States in 2018.1 Papillary thyroid cancers
(PTC) account for 65%‐88% of all thyroid cancers.2 Post‐thyroidectomy pathological findings play an important role in
prognosis, and along with patient age and total body iodine
uptake scan, comprise the three‐tiered risk stratification system endorsed in the American Thyroid Association (ATA)
2015 guidelines to predict risk of recurrent disease.3 Rates of
recurrence vary widely within risk groups,3 reflecting residual heterogeneity. Differences in tumor biology may explain
much of the variability, and molecular markers of aggressive
disease have been proposed to further stratify the three‐tiered
risk system.
The proto‐oncogene BRAF V600E mutation has been
extensively studied and characterized in the PTC literature,
though with conflicting associations with recurrence in multiple studies. A pooled meta‐analysis of 14 studies including
2470 PTC patients found BRAF mutation was associated with
twice the risk of recurrence (24.9% vs 12.6%, P < 0.00001).4
It is unclear whether BRAF mutation independently confers
additional risk as it is often linked to aggressive histological findings.5 Though BRAF mutation is quite prevalent
(30%‐80%),6 even in the intermediate‐ and high‐risk groups,
BRAF mutation alone is not consistently prognostic. In our
prior institutional series of 508 PTC patients with 8‐year
median follow‐up, nearly half of the patients had multifocal
disease, extrathyroidal extension, and cervical nodes. BRAF
V600E mutation was prevalent (67%), but was not associated
with recurrence or disease‐specific survival.7 This suggests
that additional molecular drivers may be responsible for aggressive cPTC.
The Cancer Genome Atlas (TCGA) recently reported their
analysis of 496 PTC samples and found significant genetic variation amongst the BRAF mutant cohort.8 In their analysis, two
common oncogenic pathways were identified: (a) BRAF mutation constitutively activating mitogen‐activated protein kinase
kinase (MEK) and mitogen‐activated protein kinase (MAPK),
and (b) RAS activating both PI3 kinase/phosphorylated AKT
(pAKT) and the MAPK/Extracellular Signal‐Related Kinase
(ERK) pathway. Upstream of either proposed pathway is the
RET proto‐oncogene (RET). Downstream effects of cell proliferation and dedifferentiation are thought to promote tumor
growth, invasiveness, and resistance to radioactive iodine.8,9
It is possible that genetic, transcriptional, or post‐translational
regulation of factors along this pathway could have similar

downstream effects even in the absence of upstream genetic
activation. Therefore, we sought to characterize the molecular
expression at the protein level of five factors along the BRAF
and RAS pathways in a large single institution cohort of PTC
patients with long clinical follow‐up. We sought to identify
molecular signatures that may be associated with clinical
outcomes.
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Patient selection

|

BRAF V600E mutation analysis

|

Immunohistochemistry analysis

Patients referred to Radiation Oncology from 1973 to 2009
with a diagnosis of classic papillary histology thyroid cancer
(cPTC) who underwent thyroidectomy and had available archived tumor specimens were included. Other histologic variants of PTC, including follicular and tall cell variants, were
specifically excluded. This retrospective study was approved
by the institutional review board with waiver of consent.

2.2

BRAF V600E mutation status was determined as previously published.7 Briefly, thyroid tumor specimens were
unarchived from formalin‐fixed, paraffin‐embedded (FFPE)
biopsies. Tissue slides stained with hematoxylin and eosin
were examined and marked by a board certified pathologist
(JP) to identify areas of cPTC. For BRAF mutation status,
total RNA was isolated from two tissue cores of 1 mm diameter and the BRAF exon was amplified with polymerase
chain reaction (PCR). BRAF V600E mutation was identified
with restriction fragment length polymorphism (RFLP) analysis, which has been previously validated.7

2.3

A tissue microarray (TMA) was constructed from the
same FFPE samples. Areas of cancer were punched with
1.5 mm cores and placed in triplicate into recipient blocks.
IHC stains for RET (C‐19; Santa Cruz Biotechnology,
Dallas, TX), phospho‐MEK (pMEK; 166F8; Cell
Signaling Technology, Danvers, MA), phospho‐p44/42
MAPK (dpERK; Erk1/2, Thr202/Tyr204, 20G11; Cell
Signaling Technology), PPARγ (SC‐7273P; Santa Cruz
Biotechnology), and phospho‐AKT (pAKT; Ser473,
Thr308; Cell Signaling Technology) were scored independently and blindly by two investigators on a scale of 0‐3
for staining intensity and percentage of stain positive cells.
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The initial scoring of 0 to 3 was chosen to better characterize the range of staining intensity/percent positive seen in
the cohort. Examples of control slides staining and each
score for the TMA are presented in Supplemental Figures
S1 and S2, respectively. An average score of ≥2 was categorized as positive, as judged by either investigator, and
<2 was categorized as negative. Concordance in scoring
between both investigators was determined to document
interpersonal scoring heterogeneity.

2.4

|

Treatment and follow‐up

All patients underwent thyroidectomy. Post‐operative radioactive iodine (RAI) was administered to 215 patients. Whole‐
body scans were typically performed post‐RAI ablation, and
surveillance total body scans were performed after thyroid
hormone withdrawal at 1 year following RAI. Non‐palpable
persistent disease on the whole‐body scan was treated with additional RAI. Surveillance consisted of physical examination
and laboratory studies including thyroid stimulating hormone
(TSH), triiodothyronine, and free thyroxine with the addition of thyroglobulin levels in the latter years of the study.
Recurrence was defined as either positive disease found on the
whole‐body scan in a previously negative area, positive disease seen on other clinical imaging (eg, neck ultrasound or CT
scan), or pathologically proven recurrence. Metastatic patients
who never responded to RAI and had continued progression
of disease were also coded as recurrent at time of diagnosis.

2.5

|

Statistics

Concordance of TMA scoring was evaluated with Cohen’s
kappa,10 with a cutoff score above 0.4 required to be included
in further analysis. Two‐tailed student’s t tests were used to
compare continuous variables, and Fisher’s exact tests were
used to compare categorical variables. Significant differences were considered if P < 0.05. Binary logistic regression
was used to identify significant clinicopathologic factor associations with each molecular marker. Kaplan‐Meier and
log‐rank tests were used for freedom from recurrence (FFR)
and cancer‐specific survival (CSS). Univariable and multivariable Cox regression was used to model predictors of recurrence and thyroid cancer death. Results were considered
significant if the 95% confidence interval (CI) did not cross
one.
In order to determine molecular risk classification,
recursive partition analysis (RPA) was conducted for the
outcome of disease utilizing survival trees. Pruning was
completed, when necessary, by recursively snipping off
the least important splits based on the complexity parameter (CP). All statistical analyses were done with R version 3.03, SAS version 9.4, and SPSS, version 23 (IBM,
Armonk, NY).
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RESULTS

|

Patients and treatments

|

TMA scoring concordance

A total of 1712 patients with a diagnosis of thyroid cancer
were referred to our department from 1973 to 2009. A total
of 383 patients with cPTC histology who underwent partial
or total thyroidectomy had available tumor specimens. Of
these patients, 244 had adequate archived tumor specimen
for molecular analyses. A total of 231/244 (95%) patients had
interpretable IHC stains on the TMA and were included for
analysis. The final cohort had a mean follow‐up of 10.1 years
(range 0.1‐40 years).
Patient and tumor characteristics are detailed in Table
1. The majority were adult (n = 212) compared to pediatric
(≤21 years of age; n = 19). Mean age for adult patients was
47 years (range 23‐82 years) compared to 16 years (range
6‐21 years) for pediatric patients. Cervical lymph node dissection was done in 49% of cases. Adjuvant I‐131 was given
to 94% of patients in this study. Tumor size and nodal stage
were significantly higher in pediatric patients. ATA risk
groups were represented equally between adult and pediatric
patients. The majority of patients had intermediate‐ (32%) or
high‐risk (42%) disease.

3.2

Two investigators independently scored the IHC staining on
the TMAs on a scale from 0 to 3, and their average scores
for the two to three cores per patient were compared. An average score greater than or equal to two from at least one
investigator was considered positive. Concordance in scoring
between investigators was 72%, 87%, 93%, 85%, and 88%
for RET, pMEK, MAPK (dpERK), pAKT, and PPARγ, respectively. Cohen’s kappa was 0.46 (95% CI 0.38‐0.54), 0.14
(95% CI −0.09‐0.37), 0.68 (95% CI 0.57‐0.79), 0.68 (95%
CI 0.61‐0.75), and 0.63 (95% CI 0.53‐0.73) for RET, pMEK,
MAPK (dpERK), pAKT, and PPARγ, respectively. pMEK
staining was positive in 26/184 (14%) of patients, but the
two investigators only agreed on 6 of the 26 positive scores.
Cohen’s kappa for MEK crossed zero, and thus, MEK staining was excluded in further analyses.

3.3 | Association of molecular markers with
clinicopathologic factors
The overall rate of BRAF V600E mutation in this population was 74%, with similar incidence in both adult and
pediatric patient populations. BRAF V600E mutation was
significantly enriched in the ATA intermediate‐ (73%) and
high‐risk (82%) groups compared to low‐risk (61%) patients
(P = 0.01; Table 2). BRAF V600E mutation was associated
with clinical stage T3‐4 (OR 2.2, 95% CI 1.2‐4.2), capsular

|
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Patient and tumor characteristics
Total (n = 231)

Adult (n = 212)

Pediatric (n = 19)

170/231 (74%)

156/212 (72%)

14/19 (74%)

1.00

Positive pAKT IHC

83/212 (39%)

75/194 (39%)

8/18 (44%)

0.62

Positive MAPK IHC

29/206 (14%)

28/188 (15%)

1/18 (6%)

0.48

124/205 (61%)

120/189 (64%)

4/16 (25%)

0.006

53/194 (27%)

50/177 (28%)

3/17 (18%)

0.57

65 (28%)

61 (29%)

4 (21%)

0.60

Female

166 (72%)

151 (71%)

15 (79%)

White

197 (85%)

181 (85%)

16 (84%)

Black

17 (7%)

17 (8%)

0 (0%)

Asian

13 (6%)

11 (5%)

2 (11%)

BRAF V600E mutation

Positive RET IHC
Positive PPARγ IHC
Male

Hispanic
Mean age (range)

P value

0.18

4 (2%)

3 (2%)

1 (5%)

44 (6‐82)

47 (23‐82)

16 (6‐21)

<0.001

Lymph node dissection

116 (50%)

103 (49%)

13 (68%)

0.15

Median Post‐op I‐131 dose (mean, range)

105 (0‐230)

105 (0‐230)

125 (0‐175)

0.49

Mean tumor size (range)

2.03 (0.1‐8.5)

1.99 (0.1‐8.5)

2.45 (0.8‐4.5)

0.10
0.01

T1

94 (41%)

91 (43%)

3 (16%)

T2

45 (20%)

38 (18%)

7 (37%)

T3

23 (10%)

23 (11%)

0 (0%)

T4

68 (29%)

59 (28%)

9 (47%)

N0

116 (50%)

110 (52%)

6 (32%)

N1a

76 (33%)

71 (34%)

5 (26%)

N1b

38 (17%)

30 (14%)

8 (42%)

M0

220 (96%)

202 (96%)

18 (95%)

M1

10 (4%)

9 (4%)

1 (5%)

154 (67%)

136 (65%)

18 (95%)

0.01

0.59

AJCC stage
I
II

14 (6%)

13 (6%)

1 (5%)

III

54 (24%)

54 (26%)

0 (0%)

IV

7 (3%)

7 (3%)

0.02

0 (0%)

Multifocal

112/230 (49%)

108/211 (50%)

9/19 (47%)

1.00

Capsular invasion

134/230 (58%)

123/211 (58%)

11/19 (58%)

1.00

Vascular invasion

34/230 (15%)

27/211 (13%)

7/19 (37%)

0.01

Soft tissue invasion

92/230 (40%)

81/211 (38%)

11/19 (58%)

0.14

Positive margins

85/230 (37%)

75/211 (36%)

10/19 (53%)

0.15
0.25

Tumor location
Thyroid only

113 (49%)

107 (50%)

6 (32%)

Thyroid and neck nodes

107 (46%)

95 (45%)

12 (63%)

Thyroid, nodes, and lung

9 (4%)

8 (4%)

51 (5%)

Thyroid and bone

1 (0.5%)

1 (0.5%)

0 (0%)

Unspecified

1(0.5%)

1 (0.5%)

0 (0%)

61 (26%)

56 (26%)

ATA 2015 risk group
Low

5 (26%)

Intermediate

74 (32%)

71 (34%)

3 (16%)

High

96 (42%)

85 (40%)

11 (58%)

AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; IHC, immunohistochemistry.

0.21
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Molecular marker expression in ATA low‐, intermediate‐, and high‐risk groups
ATA low risk (%)

ATA intermediate risk
(%)

ATA high risk (%)

P value

BRAF V600E mutation

37/61 (61)

54/74 (73)

79/96 (82)

0.01

Positive pAKT IHC

23/56 (41)

29/67 (43)

31/89 (35)

0.54

Positive MAPK IHC

9/53 (17)

10/64 (16)

10/89 (11)

0.58

Positive RET IHC

34/55 (62)

40/64 (63)

50/86 (58)

0.86

Positive PPARγ IHC

19/51 (37)

19/60 (32)

15/83 (18)

0.03

ATA, American Thyroid Association; IHC, immunohistochemistry.

invasion (OR 2.0, 95% CI 1.1‐3.6), and soft tissue invasion
(OR 2.3, 95% CI 1.2‐4.4). BRAF V600E mutation was inversely linked to MAPK (dpERK) IHC intensity (OR 0.43,
95% CI 0.19‐0.97), but was not associated with other molecular markers (Supplemental Table S1).
The overall rate of positive RET staining was 61%.
Pediatric patients had significantly lower rates of positive
RET staining compared to adults (25% vs 64%, P = 0.002).
Males also were less likely to have tumors staining positive
for RET (OR 0.39, 95% CI 0.21‐0.72). There was no difference in RET staining among the ATA risk groups. RET
staining did not have any association with BRAF V600E mutation, but was positively associated with pAKT and PPARγ
(Supplemental Table S1).
The rates of pAKT, MAPK (dpERK), and PPARγ positive staining were 39%, 14%, and 27%, respectively. There
were no significant differences between adult and pediatric
patients. PPARγ positive staining was less likely in the ATA
high‐risk group (Table 2). PPARγ positive tumors were less
likely to be T3‐4 clinical stage (OR 0.75, 95% CI 0.58‐0.97),
lymph node positive (OR 0.38, 95% CI 0.20‐0.74), multifocal (OR 0.44, 95% CI 0.23‐0.85), and less likely to have soft
tissue invasion (OR 0.41, 95% CI 0.21‐0.83), or positive margins (OR 0.35, 95% CI 0.17‐0.73). pAKT, MAPK (dpERK),
and PPARγ co‐expression was common (Supplemental Table
S1).

3.4 | Recurrence and cancer‐
specific mortality
Recurrence occurred in 34/231 (14.7%) of cPTC patients during a mean of 10 years of follow‐up. Of these, 3 (9%) recurred in the thyroid bed alone, 23 (67%) recurred in neck
lymph nodes, 4 (12%) recurred in distant sites, and 4 (12%)
patients never achieved remission from distant disease since
their initial surgery. Rates of recurrence in the ATA low‐,
intermediate‐, and high‐risk groups were 5%, 10%, and 25%,
respectively (P = 0.001). There was no significant difference in recurrence between ATA low‐ and intermediate‐risk
groups (Table 3). However, the estimated 10‐year FFR was
significantly worse in the ATA high‐risk group compared

to the pooled low‐ and intermediate‐risk groups in Kaplan‐
Meier analysis (74% vs 95%, P < 0.001, Figure 1A). RET
expression was inversely associated with recurrence (HR
0.46, 95% CI 0.22‐0.96). No other molecular markers were
independently associated with recurrence in this patient population (Table 3).
There were 9/231 (3.9%) deaths attributed to thyroid cancer. Rates of cancer‐specific death in the ATA low‐, intermediate‐, and high‐risk groups were 0%, 1.4%, and 8.3%,
respectively (P = 0.01). Cancer‐specific death was significantly associated with older age, higher T stage, metastatic
disease, vascular invasion, soft tissue invasion, and positive
margins (Table 3). No single molecular marker was independently associated with cancer‐specific death.

3.5 | Molecular recursive
partitioning analysis
In exploratory analysis, we sought to identify a molecular signature that independently predicts a high risk of recurrence. RET, the only marker independently associated
with recurrence, was chosen as the initial branch point of
a recursive partitioning tree. The other molecular markers
(BRAF, MAPK (dpERK), pAKT, PPARγ) were tested as
branch points to enrich for a “molecular high‐risk group”
(Supplemental Figure S1). BRAF V600E mutation did not
meet significance as a branch point in any iteration of the
RPA. The final model is depicted in Figure 2. Positive
RET staining was associated with a low risk of recurrence
(10%). Patients whose tumors had negative RET staining
and either positive pAKT or MAPK (dpERK) staining had
a high risk of recurrence (42%). Patients whose tumors
were negative for RET, pAKT, and MAPK (dpERK) had a
16% risk of recurrence and were grouped with the patients
whose tumors stained positive for RET as part of a “molecular low‐risk group.” The estimated 10‐year freedom
from recurrence was significantly lower in the molecular
high‐risk group compared to the molecular low‐risk group
(57% vs 90%, P < 0.001, Figure 2B). Incidence of cancer‐specific death in the molecular low‐risk and molecular
high‐risk groups was 3% and 13%, respectively (P = 0.03).
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Recurrence (Hazard ratio, 95%
CI) n = 34/231

Cancer death (Hazard
ratio, 95% CI) n = 9/231

BRAF V600E mutation

1.56 (0.68‐3.59)

3.48 (0.43‐27.9)

Positive pAKT IHC

1.09 (0.53‐2.25)

0.60 (0.12‐2.95)

Positive MAPK IHC

1.57 (0.65‐3.84)

0.71 (0.09‐5.70)

Positive RET IHC

0.46 (0.22‐0.96)

0.45 (0.11‐1.91)

Positive PPARγ IHC

0.37 (0.11‐1.23)

1.01 (0.21‐4.93)

Molecular high‐risk score

5.57 (2.56‐12.1)

4.73 (1.12‐19.9)

Age

1.00 (0.98‐1.03)

1.05 (1.01‐1.10)

Male vs female

1.47 (0.72‐2.97)

1.96 (0.52‐7.30)

TABLE 3

Univariable analyses of
recurrence and cancer‐specific death and
their associations with molecular and
clinicopathologic factors. Hazard ratios and
95% confidence intervals (CI) are noted for
recurrence and cancer‐specific death

Race
White (Ref)

Ref

Ref
Unable to calculate HRb

Black

0.38 (0.05‐2.82)

Asian

0.99 (0.23‐4.20)

Hispanic

2.03 (0.28‐14.9)

Tumor size

1.37 (1.18‐1.59)

1.28 (0.95‐1.73)

T3‐4 vs T1‐2

3.10 (1.54‐6.28)

12.3 (1.53‐98.3)

Node positive

5.25 (2.17‐12.7)

7.85 (0.98‐62.8)

M1 vs M0

7.47 (2.85‐19.6)

16.1 (3.82‐67.8)

1.85 (0.23‐14.9)
Unable to calculate HRb

AJCC stage
3.42 (1.74‐6.72)

26.3 (3.26‐211)

Multifocal

2.29 (1.10‐4.76)

7.80 (0.96‐63.6)

Capsular invasion

3.06 (1.33‐7.07)

Vascular invasion

5.02 (2.48‐10.2)

5.26 (1.31‐21.2)

Soft tissue invasion

3.37 (1.63‐6.95)

10.9 (1.34‐88.9)

Positive margins

2.59 (1.30‐5.18)

12.4 (1.52‐101)

First I‐131 dose

1.00 (0.99‐1.01)

1.01 (0.99‐1.03)

III‐IV vs I‐II

Unable to calculate HRc

ATA risk
Low

Ref

Ref

Intermediate

2.01 (0.52‐7.77)

Unable to calculate HRc

High

5.90 (1.78‐19.6)

Unable to calculate HRc

a
Bolded text signified the table variable was statistically significant.
AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; IHC, immunohistochemistry; Ref, reference variable.
b
No cancer death in patient group.
c
No cancer death in reference group.

Incidence of both BRAF mutation and PPARγ expression was not different between the low‐risk and high‐risk
molecular score groups (BRAF: 73% vs 75%, respectively,
P = 0.82; PPARγ: 27% vs 30%, respectively, P = 0.70). The
presence of BRAF V600E mutation was not associated with
risk of recurrence in either the molecular low‐risk (log‐rank
P = 0.34) or high‐risk groups (log‐rank P = 0.16).

3.6 | Comparison of ATA risk and
molecular score risk
The molecular high‐risk profile was found in 9%, 14%, and
13% of ATA low‐, intermediate‐, and high‐risk groups,

respectively (P = 0.77), suggesting the prognostic information gained from each of the two risk stratifications is
unique. In a multivariable model, recurrence was independently associated with both ATA high risk (HR = 2.8, 95%
CI 1.3‐6.0, P = 0.008) and the molecular high‐risk signature (HR = 5.4, 95% CI 2.5‐12, P < 0.001). Cancer‐specific
death was also independently associated with both ATA high
risk (HR = 9.3, 95% CI 1.1‐76, P = 0.04) and the molecular
high‐risk signature (HR = 4.3, 95% CI 1.0‐18, P = 0.05).
The 5‐year estimated FFR in ATA low‐/intermediate‐risk
patients stratified by molecular risk was 99% (molecular
low risk) vs 64% (molecular high risk), P < 0.001 (Figure
1C). The 5‐year estimated FFR in ATA high‐risk patients
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F I G U R E 1 Kaplan‐Meier analysis for freedom from recurrence (FFR). A, FFR of patients stratified by ATA risk groups, B, FFR of patients
stratified by a proposed molecular score. C, FFR of patients stratified by both ATA risk groups and a proposed molecular score

stratified by molecular risk was 83% (molecular low risk) vs
47% (molecular high risk), P < 0.001 (Figure 1C).

4
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D IS C U SSION

This large retrospective study of cPTC patients at a single institution characterized the expression of factors upstream and
downstream along the BRAF/MAPK/ERK and RAS/pAKT
pathways. We observed differences in RET tumor staining between adult and pediatric patients, and differences in
BRAF V600E mutation between ATA risk groups. Clinical
follow‐up of up to 20 years in this cohort allowed adequate
time for recurrences and cancer‐specific survival to be assessed. As expected, recurrence was more likely in the ATA

high‐risk group (25%). Only 5% and 10% of the ATA low‐
and intermediate‐risk patients recurred, respectively, which
is comparable to prior reports.3 With the exception of RET
expression, the molecular markers individually did not associate with recurrence risk. However, a proposed molecular
risk stratification was identified from recursive partitioning
analysis of multiple molecular markers. Patients whose tumors displayed the molecular high‐risk group of RET‐negative and either pAKT‐positive or MAPK (dpERK)‐positive
IHC had quadruple the risk of recurrence compared to the
low‐risk group. The molecular risk score also assigned risk of
recurrence independent of classic pathologic findings, suggesting molecular subtypes of cPTCs may explain some of
the heterogeneity seen in outcomes based on the 2015 ATA
risk classification system.
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F I G U R E 2 Recursive partitioning
analysis of molecular markers and
recurrence risk (RR). RET, pAKT, MAPK,
BRAF, and PPARγ were included in the
initial model, and the tree was pruned
manually

This study incorporates immunohistochemical staining of
multiple molecular markers, including RET, into a prognostic
score for disease recurrence in cPTCs ranging from ATA low
to high risk. Prior efforts to incorporate molecular prognostics have focused on tumor genetic mutations. Genetic panels
are being developed to differentiate benign from malignant
thyroid nodules.11 Niemeier et al created a model utilizing
BRAF mutation and clinicopathologic factors for predicting
extrathyroid tumor spread in papillary microcarcinomas.12
Most recently, a mutation in the telomerase reverse transcriptase (TERT) promoter with or without a concomitant BRAF
V600E mutation was found to be associated with recurrence
and cancer death risk.13,14 Several other prognostic score algorithms have been suggested, but these have not incorporated
molecular analysis of tumors.15 An advantage of IHC over
genetic analysis alone is that translated protein products and
post‐translational regulatory modifications such as activating
phosphorylation of kinases can be qualitatively assessed.
Similar to our prior report,7 in this cohort, BRAF V600E
mutation was not associated with recurrence or death.
Rather, MAPK (dpERK) staining in the absence of RET
staining was highly associated with recurrence and death.
MAPK (dpERK)/ERK is a kinase activated downstream of
both the BRAF and RAS pathways, and participates in proliferation and dedifferentiation.16 Intriguingly, positive IHC
staining of MAPK (dpERK) in BRAF mutant tumors was
half as likely as in BRAF wild‐type tumors in this study.
Activated pMEK staining was also significantly lower
(14%) in this population than the percentage of BRAF mutants (74%) would suggest. This finding has been observed
in human PTC samples17 as well as in melanoma, atypical
nevi, and common nevi.18 Zuo et al showed in 42 human
papillary thyroid cancer samples that only 7.1% of PTCs
with BRAF mutation had activated MAPK (dpERK)/ERK.
In contrast, 29% of wild‐type BRAF PTCs had activated
MAPK (dpERK). In their cohort, BRAF V600E mutation

was not associated with any negative clinicopathologic
factors except for age >45 years.17 These data corroborate
findings in a large 459 patient study from the University of
California, San Francisco, in which BRAF V600E mutation
was also not associated with negative clinicopathologic factors.19 In a recent publication, BRAF V600E mutation did
not worsen cancer‐specific mortality in patients <45 years
old.20 Thus, the association of BRAF V600E mutation with
aggressive PTC pathology and clinical recurrence remains
unclear. The lack of association between BRAF mutation
and MAPK (dpERK) activation at the protein level in PTCs
could partially explain this discrepancy.
In this study, patients with RET positive tumor staining
alone were half as likely to experience recurrence compared
to patients with RET‐negative tumors. In contrast, a meta‐
analysis of eight studies with 1000 patients found RET amplification through rearrangement was associated with twice
the risk of distant metastasis.14 RET rearrangement involving
the C‐terminus tyrosine kinase domain of the protein results
in constitutive activation, and these fusion proteins are detected by the C‐terminal specific antibodies commonly used
for IHC, including the one used in this study.21,22 However,
the downstream phenotype of RET rearrangement depends
on the specific N‐terminal fusion partner. The RET/PTC3 rearrangement, mostly found in tumors from patients with prior
radiation exposure,23,24 is associated with aggressive features
such as larger tumor size, extrathyroidal extension, and nodal
metastases. On the other hand, RET rearrangements in most
sporadic PTCs are the RET/PTC1 rearrangement. These
well‐differentiated PTCs rarely dedifferentiate and tend to
have a more indolent course.21,22 Therefore, in patients without prior radiation exposure, RET activation alone appears
to be a positive prognostic biomarker. This study is limited
since we did not test for RET gene rearrangement subtype,
but only 7 (3%) patients were known to have had prior neck
radiation exposure.
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How RET rearrangement might abrogate the downstream
effects of MAPK (dpERK)‐ or pAKT‐expressing tumors remains to be elucidated. In our population, 13% and 49% of
samples staining positive for RET overexpressed MAPK
(dpERK) and pAKT, respectively. Despite activation of the
traditional BRAF/MAPK (dpERK) and RAS/pAKT pathways,
these tumors behaved indolently, with only a 10% recurrence
rate in our cohort. RET kinase activity may be important in
maintaining differentiation through micro‐ribonucleic acid
(miRNA) regulation. Prior work has shown the importance of
miRNA in silencing target genes.25 RET mutations upregulate
the biogenesis of miRNAs,26 and emerging work has identified miR30a as important in maintaining PTC differentiation
through the inhibition of lysyl oxidase.27,28 In addition, pAKT
localization has been shown to be dependent on the presence
of RET rearrangement.29 In non‐invasive areas of PTC co‐expressing RET, pAKT expression was diffuse and cytoplasmic.
This was in contrast to invasive areas of PTC without RET co‐
expression, where pAKT expression was focal and localized
in the nucleus.29 pAKT expression in our cohort was predominantly localized in the nucleus, independent of RET staining.
As 50% of the PTC patients in the previous work by Vasko et
al29 were exposed to the Chernobyl radiation accident, differences in the specific RET rearrangement (eg, RET/PTC1 vs
RET/PTC3) may account for this discrepancy. Further work is
needed to study these post‐translational interactions.
Limitations of this single institution study include the retrospective bias of patient selection/referral patterns. By omitting
patients not referred for adjuvant RAI, the results are potentially skewed to higher risk patients. However, patients in this
cohort were treated with consistent institutional guidelines and
most had long‐term follow‐up. Second, the selection of tested
molecular markers in this study was decided before the TCGA
analysis was published, and RAS and TERT mutations were
not evaluated. These should be taken into account in follow‐up
studies. Third, sampling effect and tumor heterogeneity can
complicate TMA analysis of potential biomarkers, but triplicate cores and multi‐investigator blinded analysis are known
to maximize consistency.30 Fourth, the evaluation of phosphorylated proteins by immunohistochemistry is dependent on
time to tissue fixation and other conditions ex vivo which may
change the phosphorylation state of the sample.31,32 Finally,
the proposed molecular risk score was derived statistically
from recursive partitioning analysis and is only hypothesis‐
generating. Further mechanistic work should be supported, and
prognostic scores need to be validated.
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CO NC LU S ION S

In this exploratory analysis, positive RET staining by IHC
was associated with a low risk of recurrence and death from
papillary thyroid cancer. In patients with RET‐negative

|
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tumors, positive pAKT or MAPK (dpERK) staining constituted a high molecular risk subgroup of tumors. IHC
analysis of molecular biomarkers may assist clinicians in
further stratifying risk of recurrence when combined with
the current ATA risk classifications.
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